1. T cells, particularly activated CD4⁺ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity

   • Zhaoming Wang
   • Michael S. Chimenti
   • George J. Weiner

   Original Article Open access 10 June 2021 Pages: 237 - 249

   

2. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

   • Jan Budczies
   • Martina Kirchner
   • Albrecht Stenzinger

   Original Article Open access 14 June 2021 Pages: 251 - 265

   

3. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

   • Yang Wang
   • Jun Nie
   • Jian Fang

   Original Article Open access 15 June 2021 Pages: 267 - 276

   

4. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis

   • Guanfang Liu
   • Qi Zhang
   • Erxia Shen

   Original Article 15 June 2021 Pages: 277 - 287

   

5. Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement

   • Koen A. Marijt
   • Lisa Griffioen
   • Thorbald van Hall

   Original Article Open access 17 June 2021 Pages: 289 - 300

   

6. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis

   • Ruiting Ye
   • Han Zeng
   • Zewei Wang

   Original Article 21 June 2021 Pages: 301 - 310

   

7. Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1

   • Juntao Li
   • Linqing Sun
   • Weichang Chen

   Original Article 22 June 2021 Pages: 311 - 325

   

8. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

   • Elena Fountzilas
   • Sofia Lampaki
   • Dimitrios Bafaloukos

   Original Article Open access 23 June 2021 Pages: 327 - 337

   

9. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma

   • Mamoru Harada
   • Yuichi Iida
   • Hirotsugu Uemura

   Original Article 23 June 2021 Pages: 339 - 352

   

10. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

    • Haiqing Ni
    • Lei Cao
    • Junjian Liu

    Original Article 24 June 2021 Pages: 353 - 363

    

11. Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion

    • Eiji Takeuchi
    • Yoshio Okano
    • Tsutomu Shinohara

    Original Article Open access 25 June 2021 Pages: 365 - 372

    

12. Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis

    • Gilbert Lazarus
    • Refael Alfa Budiman
    • Ikhwan Rinaldi

    Original Article 26 June 2021 Pages: 373 - 386

    

13. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

    • Hitomi Jo
    • Tatsuya Yoshida
    • Yuichiro Ohe

    Original Article 27 June 2021 Pages: 387 - 398

    

14. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma

    • Lu Yuan
    • Xixi Wu
    • Laiyu Liu

    Original Article Open access 28 June 2021 Pages: 399 - 415

    

15. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

    • Antoine Italiano
    • Philippe A. Cassier
    • Victor Moreno

    Original Article Open access 03 July 2021 Pages: 417 - 431

    

16. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

    • Staffan Holmberg-Thydén
    • Inge Høgh Dufva
    • Daniel El Fassi

    Original Article 04 July 2021 Pages: 433 - 444

    

17. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes

    • M. Alper Kursunel
    • Ekim Z. Taskiran
    • Gunes Esendagli

    Original Article Open access 06 July 2021 Pages: 445 - 459

    

18. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

    • Takashi Kobayashi
    • Katsuhiro Ito
    • Hiroyuki Nishiyama

    Original Article 07 July 2021 Pages: 461 - 471

    

19. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

    • Rama Krishna Narla
    • Hardik Modi
    • Kandasamy Hariharan

    Original Article 10 July 2021 Pages: 473 - 489

    

20. Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma

    • Chao Wang
    • Min Shi
    • Jun Zhang

    Original Article Open access 13 July 2021 Pages: 491 - 504

    

21. Correction to: OSCC cell‑secreted exosomal CMTM6 induced M2‑like macrophages polarization via ERK1/2 signaling pathway

    • Xin Pang
    • Sha‑sha Wang
    • Ya‑ling Tang

    Correction 25 November 2021 Pages: 505 - 506